Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pomerantz

Showing results (201-210 of 254) with videos related to

Pageof 26
Sort By:
Cancer|November 15, 2018
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancerRana R McKay, Lillian Werner, Susanna J Jacobus, et al.
Nature Communications|December 16, 2021
Androgen receptor and MYC equilibration centralizes on developmental super-enhancerHaiyang Guo, Yiming Wu, Mannan Nouri, et al.
BJU International|August 4, 2015
Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancerVinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, et al.
Clinical Genitourinary Cancer|January 19, 2016
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer CenterVinayak Muralidhar, Meredith M Regan, Lillian Werner, et al.
World Journal of Urology|January 20, 2024
The effect of limited english proficiency on prostate-specific antigen screening in American menBenjamin V Stone, Muhieddine Labban, Edoardo Beatrici, et al.
The Lancet. Oncology|December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort studyFabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and CrizotinibAbhishek Tripathi, Jeffrey G Supko, Kathryn P Gray, et al.
Nature Genetics|October 13, 2015
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesisMark M Pomerantz, Fugen Li, David Y Takeda, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2010
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYCNasim Ahmadiyeh, Mark M Pomerantz, Chiara Grisanzio, et al.
Cancer|June 14, 2017
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancerMark M Pomerantz, Sandor Spisák, Li Jia, et al.
Pageof 26

Showing results (201-210 of 254) with videos related to

Sort By:
Pageof 26
Cancer|November 15, 2018
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancerRana R McKay, Lillian Werner, Susanna J Jacobus, et al.
Nature Communications|December 16, 2021
Androgen receptor and MYC equilibration centralizes on developmental super-enhancerHaiyang Guo, Yiming Wu, Mannan Nouri, et al.
BJU International|August 4, 2015
Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancerVinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, et al.
Clinical Genitourinary Cancer|January 19, 2016
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer CenterVinayak Muralidhar, Meredith M Regan, Lillian Werner, et al.
World Journal of Urology|January 20, 2024
The effect of limited english proficiency on prostate-specific antigen screening in American menBenjamin V Stone, Muhieddine Labban, Edoardo Beatrici, et al.
The Lancet. Oncology|December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort studyFabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and CrizotinibAbhishek Tripathi, Jeffrey G Supko, Kathryn P Gray, et al.
Nature Genetics|October 13, 2015
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesisMark M Pomerantz, Fugen Li, David Y Takeda, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2010
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYCNasim Ahmadiyeh, Mark M Pomerantz, Chiara Grisanzio, et al.
Cancer|June 14, 2017
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancerMark M Pomerantz, Sandor Spisák, Li Jia, et al.
Pageof 26